Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey

TL;DR

This study explores Irish neurologists' views on cannabis-based medicines, highlighting a need for education and clearer access processes.

Contribution

The paper provides new insights into neurologists' perspectives on cannabis-based medicines in Ireland, emphasizing the need for education and clearer regulatory processes.

Findings

Neurologists rate their knowledge of cannabis-based medicines as average.

There is a consensus that educational programs on cannabinoids are needed.

Approximately one-third of participants have applied for cannabis-based medicines on behalf of patients.

Abstract

Advancements continue to be made in the development of medicines containing components of the Cannabis sativa L. plant. Consultants can prescribe specific cannabis-based products for a restricted set of indications in Ireland, with neurologists being at the forefront of therapy. Much debate on the therapeutic potential/efficacy of such cannabis-based products exists.

The objective of this study was to conduct a national survey to determine the perspectives/views of Irish neurologists regarding the use of cannabis-based medicines.

An online anonymous survey was conducted to capture the perspectives and experiences of neurologists in Ireland regarding cannabis-based therapeutics.

Thirty-four neurologists completed the survey in full, with study participants rating their knowledge of cannabis-based medicines as average. Data presented herein indicate that there is a need for educational programmes on the cannabinoid system and cannabinoid-based medicines, and the findings indicate that neurologists are interested in the use of cannabinoid-based medicines in their practice. Study participants were more divided with regard to the clarity of the process for accessing cannabis-based medicines, and the consensus is that the application process is unclear. Approximately one-third of participants have made an application to access medicinal cannabis-based products on behalf of a patient.

Data presented herein indicates that the majority of neurologists surveyed are aware of the current systems in place to access cannabis-based products for medicinal use in Ireland and that some engagement with these systems has taken place. A key finding is that educational programmes on the cannabinoid system and cannabis-based medicines are required.

Figures